Literature DB >> 32318975

Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies.

Guangbiao Zhou1, Saijuan Chen2, Zhu Chen3.   

Abstract

Since the outbreak of the COVID-19 pandemic in early December 2019, 81 174 confirmed cases and 3242 deaths have been reported in China as of March 19, 2020. The Chinese people and government have contributed huge efforts to combat this disease, resulting in significant improvement of the situation, with 58 new cases (34 were imported cases) and 11 new deaths reported on March 19, 2020. However, as of March 19, 2020, the COVID-19 pandemic continues to develop in 167 countries/territories outside of China, and 128 665 confirmed cases and 5536 deaths have been reported, with 16 498 new cases and 817 new deaths occurring in last 24 hours. Therefore, the world should work together to fight against this pandemic. Here, we review the recent advances in COVID-19, including the insights in the virus, the responses of the host cells, the cytokine release syndrome, and the therapeutic approaches to inhibit the virus and alleviate the cytokine storm. By sharing knowledge and deepening our understanding of the virus and the disease pathogenesis, we believe that the community can efficiently develop effective vaccines and drugs, and the mankind will eventually win this battle against this pandemic.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; control and therapeutic strategies; evidence-based medicine; pathogenesis

Mesh:

Year:  2020        PMID: 32318975      PMCID: PMC7171433          DOI: 10.1007/s11684-020-0773-x

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   9.927


  40 in total

1.  Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected].

Authors:  L Chatenoud; C Ferran; A Reuter; C Legendre; Y Gevaert; H Kreis; P Franchimont; J F Bach
Journal:  N Engl J Med       Date:  1989-05-25       Impact factor: 91.245

2.  Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection.

Authors:  John R Teijaro; Kevin B Walsh; Stuart Cahalan; Daniel M Fremgen; Edward Roberts; Fiona Scott; Esther Martinborough; Robert Peach; Michael B A Oldstone; Hugh Rosen
Journal:  Cell       Date:  2011-09-16       Impact factor: 41.582

3.  The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.

Authors:  Tao Liu; Jieying Zhang; Yuhui Yang; Hong Ma; Zhenyu Li; Jiaoyue Zhang; Ji Cheng; Xiaoyun Zhang; Yanxia Zhao; Zihan Xia; Liling Zhang; Gang Wu; Jianhua Yi
Journal:  EMBO Mol Med       Date:  2020-06-05       Impact factor: 12.137

Review 4.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.

Authors:  Rudragouda Channappanavar; Stanley Perlman
Journal:  Semin Immunopathol       Date:  2017-05-02       Impact factor: 9.623

5.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

Review 6.  The spike protein of SARS-CoV--a target for vaccine and therapeutic development.

Authors:  Lanying Du; Yuxian He; Yusen Zhou; Shuwen Liu; Bo-Jian Zheng; Shibo Jiang
Journal:  Nat Rev Microbiol       Date:  2009-02-09       Impact factor: 60.633

7.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

8.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

9.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome.

Authors:  Zhe Xu; Lei Shi; Yijin Wang; Jiyuan Zhang; Lei Huang; Chao Zhang; Shuhong Liu; Peng Zhao; Hongxia Liu; Li Zhu; Yanhong Tai; Changqing Bai; Tingting Gao; Jinwen Song; Peng Xia; Jinghui Dong; Jingmin Zhao; Fu-Sheng Wang
Journal:  Lancet Respir Med       Date:  2020-02-18       Impact factor: 30.700

10.  Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection.

Authors:  Xin Zou; Ke Chen; Jiawei Zou; Peiyi Han; Jie Hao; Zeguang Han
Journal:  Front Med       Date:  2020-03-12       Impact factor: 4.592

View more
  30 in total

Review 1.  Current perspective of COVID-19 spread across South Korea: exploratory data analysis and containment of the pandemic.

Authors:  Amarpreet Singh Arora; Himadri Rajput; Rahil Changotra
Journal:  Environ Dev Sustain       Date:  2020-08-08       Impact factor: 3.219

2.  β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19.

Authors:  Niraj Kumar Jha; Charu Sharma; Hebaallah Mamdouh Hashiesh; Seenipandi Arunachalam; Mf Nagoor Meeran; Hayate Javed; Chandragouda R Patil; Sameer N Goyal; Shreesh Ojha
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

3.  Development and Clinical Evaluation of an Immunochromatography-Based Rapid Antigen Test (GenBody™ COVAG025) for COVID-19 Diagnosis.

Authors:  Doyeong Kim; Jihoo Lee; Jyotiranjan Bal; Seul Ki Seo; Chom-Kyu Chong; Jong Ho Lee; Hyun Park
Journal:  Viruses       Date:  2021-04-29       Impact factor: 5.818

Review 4.  Nebulization of glutathione and N-Acetylcysteine as an adjuvant therapy for COVID-19 onset.

Authors:  José Fábio Santos Duarte Lana; Anna Vitória Santos Duarte Lana; Quézia Souza Rodrigues; Gabriel Silva Santos; Riya Navani; Annu Navani; Lucas Furtado da Fonseca; Gabriel Ohana Marques Azzini; Thiago Setti; Tomas Mosaner; Claudio Lopes Simplicio; Taís Mazzini Setti
Journal:  Adv Redox Res       Date:  2021-08-08

Review 5.  Organ-specific manifestations of COVID-19 infection.

Authors:  Maria Gavriatopoulou; Eleni Korompoki; Despina Fotiou; Ioannis Ntanasis-Stathopoulos; Theodora Psaltopoulou; Efstathios Kastritis; Evangelos Terpos; Meletios A Dimopoulos
Journal:  Clin Exp Med       Date:  2020-07-27       Impact factor: 3.984

6.  Partial derivative Nonlinear Global Pandemic Machine Learning prediction of COVID 19.

Authors:  Durga Prasad Kavadi; Rizwan Patan; Manikandan Ramachandran; Amir H Gandomi
Journal:  Chaos Solitons Fractals       Date:  2020-06-25       Impact factor: 9.922

Review 7.  Immunothrombosis in COVID-19: Implications of Neutrophil Extracellular Traps.

Authors:  Brandon Bautista-Becerril; Rebeca Campi-Caballero; Samuel Sevilla-Fuentes; Laura M Hernández-Regino; Alejandro Hanono; Al Flores-Bustamante; Julieta González-Flores; Carlos A García-Ávila; Arnoldo Aquino-Gálvez; Manuel Castillejos-López; Armida Juárez-Cisneros; Angel Camarena
Journal:  Biomolecules       Date:  2021-05-06

8.  Generalized myoclonus in COVID-19.

Authors:  Pablo Rábano-Suárez; Laura Bermejo-Guerrero; Antonio Méndez-Guerrero; Javier Parra-Serrano; Daniel Toledo-Alfocea; Daniel Sánchez-Tejerina; Teresa Santos-Fernández; María Dolores Folgueira-López; Judit Gutiérrez-Gutiérrez; Blanca Ayuso-García; Jesús González de la Aleja; Julián Benito-León
Journal:  Neurology       Date:  2020-05-21       Impact factor: 9.910

9.  Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension.

Authors:  Huai-Yu Wang; Suyuan Peng; Zhanghui Ye; Pengfei Li; Qing Li; Xuanyu Shi; Rui Zeng; Ying Yao; Fan He; Junhua Li; Liu Liu; Shuwang Ge; Xianjun Ke; Zhibin Zhou; Gang Xu; Ming-Hui Zhao; Haibo Wang; Luxia Zhang; Erdan Dong
Journal:  Front Med       Date:  2021-07-09       Impact factor: 9.927

Review 10.  Management of SARS-CoV-2 pneumonia.

Authors:  Caterina Sagnelli; Benito Celia; Caterina Monari; Salvatore Cirillo; Giulia De Angelis; Andrea Bianco; Nicola Coppola
Journal:  J Med Virol       Date:  2020-10-10       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.